Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. - Wikidata - awgldk - TriplyDB

Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.

Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.

http://www.wikidata.org/entity/Q33304413

about

Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy Use of androgen deprivation therapy in prostate cancer: indications and prevalence.Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.Degarelix for prostate cancer.Degarelix and its therapeutic potential in the treatment of prostate cancer.Aging and osteoporosis in breast and prostate cancer.Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer.Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer.Attitudes and knowledge of primary care physicians regarding prostate cancer screening.Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.

P2860

Q26783861-D9A23B3F-CF41-491D-9464-A11F87691680 Q30498024-F6D85BE4-7C23-4F39-86E0-FAF162605E9E Q37074379-849674DD-16F3-4560-9BB4-3223EED64930 Q37384669-CFF5862E-73DD-484B-ADFB-C619302A2FF1 Q37488225-ED15AB71-BC7A-4CCD-86BB-EA3F32C16C3A Q37510637-7EE76C38-41FE-4686-BFE5-6C554D7D9795 Q37872146-C4F0EF45-B74F-46AF-A7A3-2823EFB0F158 Q38690674-4883E800-DB32-4EEC-B223-8103782040F5 Q38785291-59665B64-75DB-4D26-993D-02E7E77AB171 Q39339490-5F503D48-4184-4464-8CB9-EEFF517DD83C Q39557196-4A1AB70A-DF2C-4E81-9A67-C2AB9E5AFF82 Q40002235-C032AA43-E661-438D-8555-7EC3C173CEB0 Q42045691-1F717094-C905-4371-9B90-2182C78BF5B8 Q46439943-A2BAFD50-EC7B-4E7C-8DAA-91B25E6F359F Q55331819-C4F404F9-80B4-49A6-BBF4-2D576908B017

P2860

Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.

http://www.wikidata.org/entity/Q33304413

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Survival in men with nonmetast ...... uantitative systematic review.

@ast

Survival in men with nonmetast ...... uantitative systematic review.

@en

Survival in men with nonmetast ...... uantitative systematic review.

@nl

type

label

Survival in men with nonmetast ...... uantitative systematic review.

@ast

Survival in men with nonmetast ...... uantitative systematic review.

@en

Survival in men with nonmetast ...... uantitative systematic review.

@nl

prefLabel

Survival in men with nonmetast ...... uantitative systematic review.

@ast

Survival in men with nonmetast ...... uantitative systematic review.

@en

Survival in men with nonmetast ...... uantitative systematic review.

@nl

P1433

Q33304413-A021AD47-DDF2-41C3-893C-EF35BE880E48

P1476

Q33304413-145CAB0B-ECD9-4127-A6B6-0E2E18BE33AE

P2093

Q33304413-83C8B60A-1E4F-4496-B069-EA16558552F3

Q33304413-87555DE7-87B9-4033-916D-87819EE6265F

Q33304413-9C912065-27FA-4427-AF85-583CA849DFBF

P2860

Q33304413-16A59506-1EF8-4B0F-A132-95B832B22E8E

Q33304413-1DBA82D6-0773-4810-A750-6AD1C8BD0D15

Q33304413-2B78F013-D1DF-44DE-8FC2-C5B1BE134A5E

Q33304413-62B5878E-57A6-4BA0-A40D-5EC08AF32FA9

Q33304413-689E4701-93EB-45D7-83DD-98A47A78D803

Q33304413-6ACEF30F-D5DA-40E4-9FEB-6E80491E70FE

Q33304413-75174DB5-1D63-44B9-BDFA-44E491139F30

Q33304413-7723B2D9-F3A8-4B27-BBC4-F706908E6CE6

Q33304413-91945A27-B83F-4F1C-AAF4-99B49FF4CDA7

Q33304413-9B6CF35C-E717-4D69-935B-C5DB592E4030

P304

Q33304413-4C239918-DD71-4B44-AB68-8450AA5C8125

P31

Q33304413-428C80C3-3330-4360-B81D-A85205B8BF52

P356

Q33304413-B5E0F4F5-8D44-4AEC-8B0E-1504A7C4E2D1

P407

Q33304413-89F140CD-B019-4C99-93EB-3171F97DD783

P433

Q33304413-1076BD17-190B-4F15-A2C0-A7EF9CA6D5EF

P478

Q33304413-AA49E8CB-DE3E-4D33-8B46-67EB8BB0A7FB

P50

Q33304413-C818B12B-5FAF-4F56-A37B-DCFA6022B0FA

P577

Q33304413-F8B05E08-2064-42B2-95BD-093BCAF101E1

P698

Q33304413-C2B1612F-6F92-4238-A94E-7BDD6BF80BCF

P932

Q33304413-9727B6F0-83D1-438D-84D8-1D93CEB96E52

P356

JCO.2007.11.1559

P1433

Journal of Clinical Oncology

P1476

Survival in men with nonmetast ...... quantitative systematic review

@en

P2093

Amanda L Blackford

http://www.w3.org/2001/XMLSchema#string

Elizabeth Garrett-Mayer

http://www.w3.org/2001/XMLSchema#string

Mario A Eisenberger

http://www.w3.org/2001/XMLSchema#string

P2860

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

P304

4998-5008

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.11.1559

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel S Antonarakis

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17971600

http://www.w3.org/2001/XMLSchema#string

P932

4133788

http://www.w3.org/2001/XMLSchema#string